<p>RBO &amp; Co. LLC 在最近向证券交易委员会提交的文件中表示，在第一季度将其在强生（NYSE:JNJ - 免费报告）的持股增加了 1.2%。该基金在本季度购买了额外的 2,605 股后，持有该公司 216,179 股股票。强生大约占 RBO &amp; Co. LLC 持股的 5.7%，是其第三大持股。RBO &amp; Co. LLC 在强生的持股在最近一个季度末价值为 35,851,000 美元。</p>
<ul>
<li>JNJ 股票的上涨信号显示对新增长路径的信心</li>
</ul>
<p>其他几家对冲基金最近也调整了对 JNJ 的持股。Brighton Jones LLC 在第四季度将其在强生股票中的持股增加了 13.9%。Brighton Jones LLC 现在持有 51,876 股该公司的股票，价值 7,502,000 美元，此前在上个季度购买了额外的 6,332 股。Hudson Value Partners LLC 在第四季度将其在强生的持股增加了 2.5%。Hudson Value Partners LLC 现在持有 41,403 股该公司的股票，价值 5,648,000 美元，此前在上个季度收购了额外的 1,022 股。Topsail Wealth Management LLC 在第四季度购买了强生的新头寸，价值约为 369,000 美元。Voya Financial Advisors Inc.在第四季度将其在强生的持股增加了 6.0%。Voya Financial Advisors Inc.现在持有 4,998 股该公司的股票，价值 716,000 美元，此前在上个季度收购了额外的 282 股。最后，Cheviot Value Management LLC 在第四季度将其在强生的持股增加了 9.8%。Cheviot Value Management LLC 现在持有 155,318 股该公司的股票，价值 22,462,000 美元，此前在上个季度收购了额外的 13,823 股。机构投资者持有该公司 69.55% 的股票。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<h2>强生股票表现</h2>
<p>强生（JNJ）股票周五开盘价为 179.0980 美元。该公司的 50 日简单移动平均为 163.48 美元，200 日简单移动平均为 159.23 美元。该公司的速动比率为 0.76，流动比率为 1.01，债务与股本比率为 0.50。该公司的市值为 4313.3 亿美元，市盈率为 19.15，市盈增长比率为 2.28，贝塔值为 0.41。强生的 12 个月低点为 140.68 美元，12 个月高点为 181.16 美元。</p>
<ul>
<li>3 只强劲盈利的高分红股票</li>
</ul>
<p>强生（NYSE:JNJ - 获取免费报告）最近于 7 月 16 日（星期三）公布了季度财报。该公司报告本季度每股收益为 2.77 美元，超出分析师一致预期的 2.68 美元，超出幅度为 0.09 美元。该公司本季度的收入为 237.4 亿美元，而分析师预期为 228.5 亿美元。强生的净利润率为 25.00%，股本回报率为 32.49%。该公司本季度的收入同比增长 5.8%。在去年同期，该公司每股收益为 2.82 美元。强生已将其 2025 财年的指引设定为 10.800-10.900 美元的每股收益。股票研究分析师预计强生在当前财年将发布 10.58 美元的每股收益。</p>
<h2>强生宣布分红</h2>
<p>该公司还最近披露了季度分红，将于 9 月 9 日（星期二）支付。8 月 26 日（星期二）的股东将获得 1.30 美元的分红。这相当于年化分红为 5.20 美元，分红收益率为 2.9%。该分红的除息日为 8 月 26 日（星期二）。强生的派息比率目前为 55.61%。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>担心反弹减弱？考虑这 3 只分红股票</li>
</ul>
<p>几位研究分析师最近对 JNJ 股票发表了看法。Guggenheim 在 7 月 17 日（星期四）的研究报告中重申了对强生的 “中性” 评级，并将目标价设定为 167.00 美元（之前为 164.00 美元）。Wall Street Zen 在 7 月 18 日（星期五）将强生的评级从 “强力买入” 下调至 “买入”。Leerink Partners 在 5 月 13 日（星期二）的研究报告中将强生的评级从 “跑赢大盘” 下调至 “市场表现”，并将该股票的目标价从 169.00 美元下调至 153.00 美元。瑞银集团在 7 月 17 日（星期四）将强生的目标价从 180.00 美元上调至 190.00 美元，并给予该股票 “买入” 评级。最后，加拿大皇家银行在 7 月 17 日（星期四）将强生的目标价从 181.00 美元上调至 185.00 美元，并给予该股票 “跑赢大盘” 评级。两位研究分析师对该股票给予了 “强力买入” 评级，九位给予了 “买入” 评级，九位给予了 “持有” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价为 176.29 美元。</p>
<p><strong>阅读我们关于 JNJ 的最新股票报告</strong></p>
<h2>关于强生</h2>
<p>（免费报告）</p>
<p>强生是一家控股公司，专注于医疗领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>为什么理解期权交易量对成功的期权交易至关重要</li>
<li>MarketBeat 周评 – 08/18 - 08/22</li>
<li>内部人士出售解释：它能否影响你的投资选择？</li>
<li>皇家加勒比的盈利超出预期，推动强劲的 2025 年展望</li>
<li>澳大利亚证券交易所（ASX）是什么</li>
<li>Alphabet 的突破潜力：从落后者到 AI 领导者</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在强生吗？</h2>
<p>在考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>RBO & Co. LLC 在第一季度将其在强生（NYSE: JNJ）的持股增加了 1.2%，目前持有 216,179 股，价值 3585 万美元。其他对冲基金也增加了在 JNJ 的持仓。该股票开盘价为 179.10 美元，市值为 4313.3 亿美元，市盈率为 19.15。强生报告第二季度每股收益为 2.77 美元，超出预期，并宣布季度股息为 1.30 美元，收益率为 2.9%。分析师的评级意见不一，目标价格范围从 153 美元到 190 美元</p>

<p>RBO &amp; Co. LLC grew its holdings in Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 1.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 216,179 shares of the company's stock after purchasing an additional 2,605 shares during the quarter. Johnson &amp; Johnson makes up approximately 5.7% of RBO &amp; Co. LLC's holdings, making the stock its 3rd biggest holding. RBO &amp; Co. LLC's holdings in Johnson &amp; Johnson were worth $35,851,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>RBO &amp; Co. LLC 在最近向证券交易委员会提交的文件中表示，在第一季度将其在强生（NYSE:JNJ - 免费报告）的持股增加了 1.2%。该基金在本季度购买了额外的 2,605 股后，持有该公司 216,179 股股票。强生大约占 RBO &amp; Co. LLC 持股的 5.7%，是其第三大持股。RBO &amp; Co. LLC 在强生的持股在最近一个季度末价值为 35,851,000 美元。</p>
</div><ul>
<li>JNJ Stock Surge Signals Confidence in New Growth Path</li>
</ul>
<div class="lb-trans"><ul>
<li>JNJ 股票的上涨信号显示对新增长路径的信心</li>
</ul>
</div><p>Several other hedge funds also recently modified their holdings of JNJ. Brighton Jones LLC boosted its stake in shares of Johnson &amp; Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Hudson Value Partners LLC boosted its stake in Johnson &amp; Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after acquiring an additional 1,022 shares during the last quarter. Topsail Wealth Management LLC bought a new position in Johnson &amp; Johnson during the 4th quarter worth approximately $369,000. Voya Financial Advisors Inc. boosted its stake in Johnson &amp; Johnson by 6.0% during the 4th quarter. Voya Financial Advisors Inc. now owns 4,998 shares of the company's stock worth $716,000 after acquiring an additional 282 shares during the last quarter. Finally, Cheviot Value Management LLC boosted its stake in Johnson &amp; Johnson by 9.8% during the 4th quarter. Cheviot Value Management LLC now owns 155,318 shares of the company's stock worth $22,462,000 after acquiring an additional 13,823 shares during the last quarter. Institutional investors own 69.55% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也调整了对 JNJ 的持股。Brighton Jones LLC 在第四季度将其在强生股票中的持股增加了 13.9%。Brighton Jones LLC 现在持有 51,876 股该公司的股票，价值 7,502,000 美元，此前在上个季度购买了额外的 6,332 股。Hudson Value Partners LLC 在第四季度将其在强生的持股增加了 2.5%。Hudson Value Partners LLC 现在持有 41,403 股该公司的股票，价值 5,648,000 美元，此前在上个季度收购了额外的 1,022 股。Topsail Wealth Management LLC 在第四季度购买了强生的新头寸，价值约为 369,000 美元。Voya Financial Advisors Inc.在第四季度将其在强生的持股增加了 6.0%。Voya Financial Advisors Inc.现在持有 4,998 股该公司的股票，价值 716,000 美元，此前在上个季度收购了额外的 282 股。最后，Cheviot Value Management LLC 在第四季度将其在强生的持股增加了 9.8%。Cheviot Value Management LLC 现在持有 155,318 股该公司的股票，价值 22,462,000 美元，此前在上个季度收购了额外的 13,823 股。机构投资者持有该公司 69.55% 的股票。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><h2>Johnson &amp; Johnson Stock Performance</h2>
<div class="lb-trans"><h2>强生股票表现</h2>
</div><p>Shares of JNJ stock opened at $179.0980 on Friday. The company's fifty day simple moving average is $163.48 and its 200-day simple moving average is $159.23. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market cap of $431.33 billion, a PE ratio of 19.15, a P/E/G ratio of 2.28 and a beta of 0.41. Johnson &amp; Johnson has a 12 month low of $140.68 and a 12 month high of $181.16.</p>
<div class="lb-trans"><p>强生（JNJ）股票周五开盘价为 179.0980 美元。该公司的 50 日简单移动平均为 163.48 美元，200 日简单移动平均为 159.23 美元。该公司的速动比率为 0.76，流动比率为 1.01，债务与股本比率为 0.50。该公司的市值为 4313.3 亿美元，市盈率为 19.15，市盈增长比率为 2.28，贝塔值为 0.41。强生的 12 个月低点为 140.68 美元，12 个月高点为 181.16 美元。</p>
</div><ul>
<li>3 Big Dividend Plays With Strong Earnings to Back Them</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只强劲盈利的高分红股票</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson &amp; Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.82 earnings per share. Johnson &amp; Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts expect that Johnson &amp; Johnson will post 10.58 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）最近于 7 月 16 日（星期三）公布了季度财报。该公司报告本季度每股收益为 2.77 美元，超出分析师一致预期的 2.68 美元，超出幅度为 0.09 美元。该公司本季度的收入为 237.4 亿美元，而分析师预期为 228.5 亿美元。强生的净利润率为 25.00%，股本回报率为 32.49%。该公司本季度的收入同比增长 5.8%。在去年同期，该公司每股收益为 2.82 美元。强生已将其 2025 财年的指引设定为 10.800-10.900 美元的每股收益。股票研究分析师预计强生在当前财年将发布 10.58 美元的每股收益。</p>
</div><h2>Johnson &amp; Johnson Announces Dividend</h2>
<div class="lb-trans"><h2>强生宣布分红</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson &amp; Johnson's payout ratio is currently 55.61%.</p>
<div class="lb-trans"><p>该公司还最近披露了季度分红，将于 9 月 9 日（星期二）支付。8 月 26 日（星期二）的股东将获得 1.30 美元的分红。这相当于年化分红为 5.20 美元，分红收益率为 2.9%。该分红的除息日为 8 月 26 日（星期二）。强生的派息比率目前为 55.61%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Worried About a Fading Rally? Consider These 3 Dividend Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>担心反弹减弱？考虑这 3 只分红股票</li>
</ul>
</div><p>Several research analysts recently weighed in on JNJ shares. Guggenheim reissued a &#34;neutral&#34; rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson &amp; Johnson in a research note on Thursday, July 17th. Wall Street Zen lowered shares of Johnson &amp; Johnson from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Friday, July 18th. Leerink Partners lowered shares of Johnson &amp; Johnson from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and reduced their price objective for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. UBS Group lifted their price objective on shares of Johnson &amp; Johnson from $180.00 to $190.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, July 17th. Finally, Royal Bank Of Canada lifted their price objective on shares of Johnson &amp; Johnson from $181.00 to $185.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $176.29.</p>
<div class="lb-trans"><p>几位研究分析师最近对 JNJ 股票发表了看法。Guggenheim 在 7 月 17 日（星期四）的研究报告中重申了对强生的 “中性” 评级，并将目标价设定为 167.00 美元（之前为 164.00 美元）。Wall Street Zen 在 7 月 18 日（星期五）将强生的评级从 “强力买入” 下调至 “买入”。Leerink Partners 在 5 月 13 日（星期二）的研究报告中将强生的评级从 “跑赢大盘” 下调至 “市场表现”，并将该股票的目标价从 169.00 美元下调至 153.00 美元。瑞银集团在 7 月 17 日（星期四）将强生的目标价从 180.00 美元上调至 190.00 美元，并给予该股票 “买入” 评级。最后，加拿大皇家银行在 7 月 17 日（星期四）将强生的目标价从 181.00 美元上调至 185.00 美元，并给予该股票 “跑赢大盘” 评级。两位研究分析师对该股票给予了 “强力买入” 评级，九位给予了 “买入” 评级，九位给予了 “持有” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价为 176.29 美元。</p>
</div><p><strong>Read Our Latest Stock Report on JNJ</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 JNJ 的最新股票报告</strong></p>
</div><h2>About Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>关于强生</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>强生是一家控股公司，专注于医疗领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>Why Understanding Call Option Volume is Essential to Successful Options Trading</li>
<li>MarketBeat Week in Review – 08/18 - 08/22</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>Royal Caribbean Earnings Beat Fuels Strong 2025 Outlook</li>
<li>What is the Australian Securities Exchange (ASX)</li>
<li>Alphabet’s Breakout Potential: From Laggard to AI Leader</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>为什么理解期权交易量对成功的期权交易至关重要</li>
<li>MarketBeat 周评 – 08/18 - 08/22</li>
<li>内部人士出售解释：它能否影响你的投资选择？</li>
<li>皇家加勒比的盈利超出预期，推动强劲的 2025 年展望</li>
<li>澳大利亚证券交易所（ASX）是什么</li>
<li>Alphabet 的突破潜力：从落后者到 AI 领导者</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

RBO & Co. LLC 增加了其在强生公司$JNJ 的股票持仓